Sanofi-aventis, one of the world’s largest diversified healthcare
companies, reports earnings for the second-quarter of 2009. CEO Chris
Viehbacher comments on Q2 earnings and the Transforming Programme.
Use these links to watch the video interview in the format of your
choice:
Windows Media Player:
http://www.eurobusinessmedia.com/interviewWmp.php?id_article=468
Flash Player:
http://www.eurobusinessmedia.com/interviewFlash.php?id_article=468
Use this link to read the interview transcript:
http://www.eurobusinessmedia.com/transcript.php?id_article=468
Topics covered in the interview include:
|
- Comments on Q2 earnings
|
|
- 8-month progress report
|
|
- Transforming Program
|
|
- Update on Lantus
|
|
- Multaq launch in the US
|
|
- Update on R&D
|
|
- H1N1 vaccine production
|
|
- Impact of H1N1 on earnings
|
|
- Shantha Biotechnics acquisition
|
|
- Revision of 2009 EPS guidance
|
|
- Message to employees
|
About Sanofi-aventis:
Sanofi-aventis, a leading global diversified healthcare company,
discovers, develops and distributes therapeutic solutions to improve the
lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN)
and in New York (NYSE : SNY).
Company website: http://en.sanofi-aventis.com/home.asp
Sanofi-aventis
Investor Relations :
IR@sanofi-aventis.com
or
Media
Relations :
MR@sanofi-aventis.com
